中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

140 records (took 0.029 seconds)

    Intelligent Offloading Insole Device
    81.
    发明申请
    Intelligent Offloading Insole Device 审中-公开

    公开(公告)号：US20180132566A1

    公开(公告)日：2018-05-17

    申请号：US15813613

    申请日：2017-11-15

    Applicant: ROSALIND FRANKLIN UNIVERSITY OF MEDICINE AND SCIENCE ,  THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS

    Inventor： Noah J. Rosenblatt ,  Ryan Crews ,  Farid Amirouche

    IPC: A43B17/03 ,  A43B3/00 ,  A43B17/02 ,  G05B15/02

    Abstract: A plantar surface pressure offloading system includes an insole capable of coupling with a shoe and interfacing with a foot. A number of compressible bladders and pressure sensors are coupled to the insole. Each bladder has an adjustable compressibility, and each pressure sensor is configured to measure a pressure exerted on a respective portion of the foot. A controller of the system can perform, for each compressible bladder, a compressibility adjustment process including (i) receiving, from a respective pressure sensor associated with a respective bladder, a signal indicative of a pressure exerted on a respective portion of the foot, (ii) determining, based on the signal, that the pressure exerted on the respective portion of the foot exceeds a threshold pressure, and (iii) responsive to the determination, adjusting the compressibility of the respective bladder, thereby offloading pressure from the respective portion of the foot to a different portion of the foot.

    Foot-strength test device and methods for use
    82.
    发明授权
    Foot-strength test device and methods for use 有权

    公开(公告)号：US09839389B2

    公开(公告)日：2017-12-12

    申请号：US14689550

    申请日：2015-04-17

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Karen Marie Stevens

    IPC: A61B5/00 ,  A61B5/22

    CPC classification number: A61B5/224

    Abstract: The present disclosure provides a device for testing the strength of a human foot. The device includes a substantially planar member having a top surface and a bottom surface. The device also includes a foot-engaging member moveable along the top surface substantially planar member from a first position to a second position. In addition, the device includes a force sensor fixed with respect to the substantially planar member, where the force sensor resists movement between the first position and the second position. Further, the device includes a tension bearing element connecting the foot-engaging member to the force sensor.

    METHODS AND KITS FOR DIAGNOSING, PROGNOSING AND MONITORING PARKINSON'S DISEASE
    84.
    发明申请
    METHODS AND KITS FOR DIAGNOSING, PROGNOSING AND MONITORING PARKINSON'S DISEASE 有权
    诊断，预防和监测帕金森病的方法和工具

    公开(公告)号：US20160244833A1

    公开(公告)日：2016-08-25

    申请号：US14870960

    申请日：2015-09-30

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Judith Ann POTASHKIN ,  Jose Alfredo SANTIAGO

    IPC: C12Q1/68

    CPC classification number: C12Q1/6883 ,  C12Q2600/158

    Abstract: Network-based meta-analysis of four independent microarray studies identified the hepatocyte nuclear factor (HNF4A), a transcription factor associated with gluconeogenesis and diabetes, as a central regulatory hub gene upregulated in blood of PD patients. In parallel, the polypyrimidine tract binding protein 1 (PTBP1), involved in the stabilization and mRNA translation of insulin, was identified as the most downregulated gene. Using both markers, PD patients were classified with 90% sensitivity and 80% specificity. Longitudinal performance analysis demonstrated that relative abundance of HNF4A and PTBP1 mRNAs significantly decreased and increased, respectively, in PD patients during 3 years follow up period. The inverse regulation of HNF4A and PTBP1 provides a molecular rationale for the altered insulin signaling observed in PD patients. The longitudinally dynamic biomarkers identified in this study may be useful for monitoring disease-modifying therapies for PD.

    Abstract translation: 四个独立的微阵列研究的基于网络的荟萃分析确定了肝细胞核因子（HNF4A），一种与糖异生和糖尿病相关的转录因子，作为PD患者血液中枢调节中枢基因。 同时，涉及胰岛素的稳定和mRNA翻译的聚嘧啶多肽结合蛋白1（PTBP1）被鉴定为最下调的基因。 使用两个标记物，PD患者被分类为90％敏感性和80％特异性。 纵向性能分析表明，3年随访期间，PD患者HNF4A和PTBP1 mRNA的相对丰度分别显着降低和升高。 HNF4A和PTBP1的逆调节为PD患者观察到的改变的胰岛素信号提供了分子依据。 在本研究中鉴定的纵向动态生物标志物可能用于监测PD的疾病修复治疗。

    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND)
    89.
    发明申请
    METHODS OF TREATING HIV-ASSOCIATED NEUROLOGICAL DISORDERS (HAND) 有权

    公开(公告)号：US20220184036A1

    公开(公告)日：2022-06-16

    申请号：US17547472

    申请日：2021-12-10

    Applicant: Rosalind Franklin University of Medicine and Science

    Inventor： Johnny HE ,  Xiaojie ZHAO

    IPC: A61K31/41 ,  A61K45/06 ,  A61P25/00 ,  A61K31/506

    Abstract: In the present disclosure, doxycycline-inducible astrocyte-specific HIV Tat transgenic mice (iTat), a surrogate HAND model, were treated with PNU-125096, a positive allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR) and effects on Tat-induced behavioral impairments and neuropathologies were observed. This disclosure shows that PNU-125096 treatment significantly improved locomotor, learning and memory deficits of iTat mice while inhibited glial activation and increased PSD-95 expression in the cortex and hippocampus of iTat mice. α7 nAChR knockout eliminated the protective effects of PNU-125096 on iTat mice. In addition, inhibition of p38 phosphorylation by SB239063, a p38 MAPK-specific inhibitor, exacerbated Tat neurotoxicity in iTat mice. These findings demonstrated for the first time that α7 nAChR activation led to protection against HAND and suggest that α7 nAChR and PNU-125096 hold significant promise for development of therapeutics for HAND.

Patent Agency Ranking